ALECTOR
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in disco... very and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
ALECTOR
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2013-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.alector.com
Total Employee:
101+
Status:
Active
Contact:
(415) 231-5660
Total Funding:
269.5 M USD
Technology used in webpage:
Domain Not Resolving Amazon Pound Sterling Japanese Yen Amazon Route 53 DigiCert SSL Amazon SSL Amazon Oregon Region Amazon Ohio Region Akamai Hosted
Similar Organizations
Audentes Therapeutics
Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Berkeley Lights
Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Invitae
Invitae is a medical genetics company that bring comprehensive genetic information into mainstream medicine to improve healthcare.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Xenothera
Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series E - Alector
Mission Bay Capital
Mission Bay Capital investment in Series E - Alector
Euclidean Capital
Euclidean Capital investment in Series E - Alector
Google Ventures
Google Ventures investment in Series E - Alector
Polaris Partners
Polaris Partners investment in Series E - Alector
Section 32
Section 32 investment in Series E - Alector
Deerfield Capital Management
Deerfield Capital Management investment in Series E - Alector
Amgen Ventures
Amgen Ventures investment in Series E - Alector
Mission BioCapital
Mission BioCapital investment in Series E - Alector
Casdin Capital
Casdin Capital investment in Series E - Alector
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-07 | INmuneBIO | Alector investment in Post-IPO Equity - INmuneBIO | 8.17 M USD |
Official Site Inspections
http://www.alector.com Semrush global rank: 2.85 M Semrush visits lastest month: 5.83 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Alector"
Our Executive Leadership & Board of Directors - Alector
Founded in 2013, we’re led by a seasoned team of inventors, scientists, and big thinkers. We combine our deep expertise in immunology, neurology, and genetics in our quest to deliver life …See details»
Alector - Crunchbase Company Profile & Funding
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related …See details»
About Us - Alector
Alector is on a mission to develop therapies that improve healthy function to the brain. By unlocking the power of immunology, neuroscience, and human genetics, we’re trailblazing immuno-neurology —a visionary therapeutic approach to …See details»
Alector Corporate Overview
Alector is not aware of any other TREM-2 activating candidates in a Phase 2 or Phase 3 trial for AD as of November 2024. AL002 (TREM2 Activator): Promising Immuno-neurology Candidate …See details»
Alector - LinkedIn
We are harnessing the immune system to treat neurodegeneration and cancer. We have always walked our own path at Alector. That’s what led us to our bold thinking and fresh, new approach of empowering the body’s immune system …See details»
Alector Corporate Overview
Alector is not aware of any other TREM2-activating candidates in a Phase 2 or a Phase 3 trial for AD, PGRN-elevating candidates in a Phase 3 trial for FTD, or PGRN-elevating candidates in a …See details»
Alector - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Alector . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 14. Number of Board …See details»
Alector Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Alector has 5 employees at their 1 location and $97.06 m in annual revenue in FY 2023. See insights on Alector including office locations, competitors, revenue, financials, …See details»
Alector
AlectorSee details»
Alector - Funding, Financials, Valuation & Investors - Crunchbase
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel. Search Crunchbase. ... Which …See details»
Alector turns to layoffs as Alzheimer’s drug fails - Yahoo Finance
5 days ago In an emailed statement, a company spokesperson said the reductions were across the organization. As of Sept. 30, Alector had $457 million in cash, cash equivalents and …See details»
GSK and Alector announce global collaboration in immuno …
Jul 2, 2021 Arnon Rosenthal, Ph.D., Chief Executive Officer, Alector, said: “This transformative collaboration brings together Alector’s leading immuno-neurology expertise with GSK’s …See details»
Our History Overview - Alector
Alector and Adimab announce strategic alliance to access antibody technologies. Co-founders Arnon Rosenthal, Ph.D., Tillman Gerngross and Errik Anderson launch Alector with …See details»
Alector lays off 17% of staff after phase 2 Alzheimer's drug fail
5 days ago Alector removed AL003 from its pipeline but continued work with AbbVie on AL002. Across both AL002 and AL003, the deal was worth up to $985.6 million in option exercise and …See details»
With GSK, Alector has the Big Pharma backing to capitalize on a …
Jan 27, 2022 RELATED: GSK, under pressure to perform, pens $2.2B deal with Alector focused on neuro R&D, Alzheimer's He cited Bristol Myers Squibb, which paid Prothena $80 million to …See details»
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
6 days ago Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected]. 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) Laura …See details»
Our Mission - Alector
At Alector, we are on a mission to slow the progression of neurodegenerative diseases and to one day prevent their occurrence. There are currently over 50 million people with …See details»
Alector stock drops after Alzheimer’s drug fails in Phase II trial
6 days ago Alector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, failed to meet the primary endpoint.. The therapy …See details»
Alector: Bleak Prospects After Alzheimer's Failure
Alector will be reducing its workforce by approximately 17%. ... In my professional life, I am the deputy director general in a leading European sector organization. I have a Master's Degree in …See details»
Culture and Careers - Alector
Because a great workplace means engaged Alectorians, and engaged Alectorians produce their best work. Alector was selected by Fortune as one of the 2023 Best Workplaces in Healthcare …See details»